Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 109512625 | 10951262 | 5 | F | 20150109 | 20160801 | 20150324 | 20160804 | EXP | PHHY2015AT017121 | NOVARTIS | 42.00 | YR | M | Y | 73.00000 | KG | 20160804 | MD | AT | AT |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 109512625 | 10951262 | 1 | PS | GILENYA | FINGOLIMOD HYDROCHLORIDE | 1 | Oral | 0.5 MG, QD | 22527 | .5 | MG | CAPSULE | QD | ||||||
| 109512625 | 10951262 | 2 | SS | GILENYA | FINGOLIMOD HYDROCHLORIDE | 1 | Oral | UNK UNK, QOD | 22527 | CAPSULE | |||||||||
| 109512625 | 10951262 | 3 | C | VENLAFAXIN | VENLAFAXINE HYDROCHLORIDE | 1 | Oral | ONCE DAILY IN THE MORNING | 0 | 150 | MG | QD | |||||||
| 109512625 | 10951262 | 4 | C | MYOCHOLINE | BETHANECHOL CHLORIDE | 1 | Oral | UNKNOWN DOSE, TID | 0 | 25 | MG | TID | |||||||
| 109512625 | 10951262 | 5 | C | MYOCHOLINE | BETHANECHOL CHLORIDE | 1 | 0 | ||||||||||||
| 109512625 | 10951262 | 6 | C | MYOCHOLINE | BETHANECHOL CHLORIDE | 1 | 0 | ||||||||||||
| 109512625 | 10951262 | 7 | C | CRANBERRY//VACCINIUM MACROCARPON | CRANBERRY | 1 | Oral | ONCE IN THE MORNING | 0 | ||||||||||
| 109512625 | 10951262 | 8 | C | CRANBERRY//VACCINIUM MACROCARPON | CRANBERRY | 1 | 0 | ||||||||||||
| 109512625 | 10951262 | 9 | C | PROSTA URGENIN | 2 | Oral | 1 DF, QD | 0 | 1 | DF | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 109512625 | 10951262 | 1 | Relapsing-remitting multiple sclerosis |
| 109512625 | 10951262 | 3 | Depression |
| 109512625 | 10951262 | 4 | Bladder dysfunction |
| 109512625 | 10951262 | 5 | Urinary retention |
| 109512625 | 10951262 | 6 | Incontinence |
| 109512625 | 10951262 | 7 | Bladder dysfunction |
| 109512625 | 10951262 | 8 | Urinary retention |
| 109512625 | 10951262 | 9 | Incontinence |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 109512625 | 10951262 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 109512625 | 10951262 | Alanine aminotransferase increased | |
| 109512625 | 10951262 | Aspartate aminotransferase increased | |
| 109512625 | 10951262 | Blood alkaline phosphatase increased | |
| 109512625 | 10951262 | Gamma-glutamyltransferase increased | |
| 109512625 | 10951262 | Liver disorder | |
| 109512625 | 10951262 | Prescribed underdose | |
| 109512625 | 10951262 | Transaminases increased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 109512625 | 10951262 | 1 | 20140519 | 20150109 | 0 | |
| 109512625 | 10951262 | 2 | 20150511 | 0 | ||
| 109512625 | 10951262 | 3 | 2014 | 0 | ||
| 109512625 | 10951262 | 4 | 2014 | 0 | ||
| 109512625 | 10951262 | 9 | 2014 | 0 |